OncoMatch

OncoMatch/Clinical Trials/NCT06601283

Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer

Is NCT06601283 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies Vitmain C plus herbal medicine for pancreatic cancer.

Phase 2/3RecruitingFudan UniversityNCT06601283Data as of Jun 2026Location: China

Treatment: Vitmain C plus herbal medicineThe purpose of this study is to evaluate the efficacy of low-dose vitamin C plus herbal medicine on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Vitmain C plus herbal medicine

Cancer type

Pancreatic Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 80

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: any anti-tumor therapy

Lab requirements

Blood counts

Hemoglobin (Hgb) ≥ 8 g/dL

Kidney function

Renal insufficiency or dialysis [excluded]

Cardiac function

Cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc) [excluded]

Adequate organ performance based on laboratory blood tests. Hemoglobin (Hgb) ≥ 8 g/dL. Renal insufficiency or dialysis [excluded]. Cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc) [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06601283 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify